Event > Webinar >

Advancing oligonucleotide therapies with liver-on-a-chip models

New oligonucleotide-based modalities, such as small interfering RNA and antisense oligonucleotides, are improving treatment options for many diseases. Since these therapeutics have human-specific targets, the need for physiologically relevant organ-on-a-chip models to assess drug delivery, efficacy, and safety continues to increase. In this webinar, Oliver Culley will explore how liver-on-a-chip technology enables researchers to delineate oligonucleotide distribution, uptake, and dosing to bridge the gap between preclinical studies and clinical success.